Civilization Ventures

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Kernal Biologics, Inc. specializes in the design and development of mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company utilizes its mRNA platform to assist researchers and organizations in creating vaccines and therapeutics. Kernal's innovative therapies instruct specific cells to produce their own therapeutic agents, thereby enhancing treatment efficacy. The company has garnered recognition for its work, receiving multiple awards from notable institutions, including Amgen and NASA. With a foundation rooted in research from MIT and Harvard, the team at Kernal Biologics possesses extensive expertise in the mRNA field, building on their prior successes in the biotechnology sector.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

Kernal Biologics, Inc. specializes in the design and development of mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company utilizes its mRNA platform to assist researchers and organizations in creating vaccines and therapeutics. Kernal's innovative therapies instruct specific cells to produce their own therapeutic agents, thereby enhancing treatment efficacy. The company has garnered recognition for its work, receiving multiple awards from notable institutions, including Amgen and NASA. With a foundation rooted in research from MIT and Harvard, the team at Kernal Biologics possesses extensive expertise in the mRNA field, building on their prior successes in the biotechnology sector.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.